Brentuximab Vedotin Plus Bendamustine: As Salvage Regimen For Relapsed Or Refractory Hodgkin Lymphoma, King Abdulaziz Medical City - Jeddah - Ksa Experience

INTRODUCTION:In advanced stage Hodgkin's Lymphoma (HL), 30% of patients experience recurrence post upfront ABVD 1.Patients with sensitive disease to salvage chemotherapy typically proceed to ASCT with curative intent 2. Achievement of CR is one of the strongest predictor of favorable outcome after ASCT3-4. Recently brentuximab vedotin plus bendamustine (BvB) became an attractive option for relapsed/refractory HL with promising efficacy and non-overlapping toxicity profiles 5-6.